Kymera Therapeutics, Inc. announced its corporate goals for 2025 on January 14, 2025, emphasizing anticipated progress on its clinical pipeline of immunology programs. The company expects 2025 to be its busiest year to date, focusing on demonstrating the clinical potential of its first-in-class, wholly-owned STAT6 and TYK2 oral degrader programs.
For KT-621 (STAT6), the Phase 1 healthy volunteer trial is ongoing, with data expected in the second quarter of 2025. Kymera plans to initiate a Phase 1b trial in atopic dermatitis (AD) patients in the second quarter of 2025, with data anticipated in the fourth quarter of 2025. Furthermore, two parallel Phase 2b trials in AD and asthma are planned to start in late 2025 and early 2026, respectively.
The company also plans to advance KT-295 (TYK2) into Phase 1 testing in the second quarter of 2025, with data expected in late 2025. The partnered KT-474/SAR444656 (IRAK4) Phase 2b dose-ranging studies in hidradenitis suppurativa (HS) and AD are ongoing, with completion expected in the first half of 2026 and mid-2026, respectively. Kymera also intends to disclose a novel oral immunology program with a first-in-class development candidate in the first half of 2025, supported by an estimated $850 million in cash as of December 31, 2024, providing a runway into mid-2027.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.